Changes of urine dihydroxyphenylglycol to norepinephrine ratio in children with attention-deficit hyperactivity disorder (ADHD) treated with atomoxetine

Journal of Child Neurology

Volumn 26, Issue 1, 2011, Pages 31-36

  Montoya, Alonso ^a   Escobar, Rodrigo ^a   García Polavieja, María J ^a   Lachno, D Richard ^b   Alda, José Ángel ^c   Artigas, Josep ^d   Cardo, Esther ^e   García, Marta ^f   Gastaminza, Xavier ^g   Gilaberte, Inmaculada ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b ELI LILLY AND COMPANY   (United States)

^c HOSPITAL SANT JOAN DE DÉU   (Spain)

^d Neuropediatrics Department   (Spain)

^e HOSPITAL SON LLÀTZER   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

ADHD; atomoxetine; attention deficit hyperactivity disorder; biomarkers; norepinephrine plasma membrane transport proteins; pharmacological; randomized controlled trial; sympathetic nervous system

Indexed keywords

3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; ATOMOXETINE; NORADRENALIN; NORADRENALIN TRANSPORTER; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT DISORDER RATING SCALE IV PARENT VERSION INVESTIGATOR; CHILD; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONCENTRATION (PARAMETERS); CONNERS PARENT RATING SCALE REVISED SHORT FORM; DISEASE MARKER; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HUMAN; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NORADRENALIN BLOOD LEVEL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHOOL CHILD; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHOXYHYDROXYPHENYLGLYCOL; NOREPINEPHRINE; PILOT PROJECTS; PROPYLAMINES; TREATMENT OUTCOME;

EID: 78651340717     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073810371981     Document Type: Article

References (31)

1. American Psychiatric Association. In: Diagnostic and Statistical Manual of Mental Disorders. Revised 4 th ed. Washington, DC: American Psychiatric Press ; 2000.
2. Faraone SV, Sergeant J., Gillberg C., Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry. 2003 ; 2: 104-113.
3. Pliszka SR The neuropsychopharmacology of attention-deficit/ hyperactivity disorder. Biol Psychiatry. 2005 ; 57: 1385-1390.
4. Biederman J., Faraone SV Attention-deficit hyperactivity disorder. Lancet. 2005 ; 366: 237-248.
5. Russell VA, Sagvolden T., Johansen EB Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct. 2005 ; 1: 9.
6. Prince J. Catecholamine dysfunction in attention-deficit/hyperactivity disorder: an update. J Clin Psychopharmacol. 2008 ; 28: S39 - S45.
7. Arnsten AF Stimulants: therapeutic actions in ADHD. Neuropsychopharmacology. 2006 ; 31: 2376-2383.
8. Pliszka SR Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev. 2007 ; 17: 61-72.
9. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 ; 27: 699-711.
10. Michelson D., Allen AJ, Busner J., et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry. 2002 ; 159: 1896-1901.
11. Michelson D., Adler L., Spencer T., et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003 ; 53: 112-120.
12. Spencer T., Heiligenstein JH, Biederman J., et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 ; 63: 1140-1147. (Pubitemid 36084059)
13. Montoya A., Hervas A., Cardo E., et al. Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009 ; 25: 2745-2754.
14. Garnock-Jones KP, Keating GM Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009 ; 11: 203-226.
15. Eisenhofer G., Kopin IJ, Goldstein DS Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev. 2004 ; 56: 331-349.
16. Vincent S., Bieck PR, Garland EM, et al. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation. 2004 ; 109: 3202-3207.
17. Bieck PR, Leibowitz M., Lachno DR, et al. Use of a biomarker of norepinephrine transporter (NET) inhibition to assess atomoxetine effects. Paper presented at the 18th ECNP Congress ; October 22-26, 2005 ; Amsterdam, The Netherlands.
18. Pliszka SR, McCracken JT, Maas JW Catecholamines in attention-deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry. 1996 ; 35: 264-272.
19. National Health Institute of Mental Health. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull. 1985 ; 21: 714-1124.
20. Conners CK Conners' Rating Scales-Revised: Technical Manual. Toronto: Multi-Health Systems ; 1997.
21. McCulloch CE, Searle SR In: Generalized, Linear and Mixed Models. 1st ed. New York, NY: Wiley-Interscience ; 2001.
22. Grace AA Psychostimulant actions of dopamine and limbic system function: relevance to the pathophysiology and treatment of ADHD. In: Solanto MV, Arnsten AFT, Castellanos FX, eds. Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. 1st ed. New York, NY: Oxford University Press ; 2001: 134-157.
23. Ernst M., Liebenauer LL, Tebeka D., et al. Selegiline in ADHD adults: plasma monoamines and monoamine metabolites. Neuropsychopharmacology. 1997 ; 16: 276-284.
24. Llorente AM, Voigt RG, Jensen CL, et al. Performance on a visual sustained attention and discrimination task is associated with urinary excretion of norepinephrine metabolite in children with attention-deficit/hyperactivity disorder (AD/HD). Clin Neuropsychol. 2006 ; 20: 133-144.
25. Oades RD Differential measures of 'sustained attention' in children with attention-deficit/hyperactivity or tic disorders: relations to monoamine metabolism. Psychiatry Res. 2000 ; 93: 165-178.
26. Zametkin A., Rapoport JL, Murphy DL, et al. Treatment of hyperactive children with monoamine oxidase inhibitors. II. Plasma and urinary monoamine findings after treatment. Arch Gen Psychiatry. 1985 ; 42: 969-973.
27. Gizer IR, Ficks C., Waldman ID Candidate gene studies of ADHD: a meta-analytic review. Hum Genet. 2009 ; 126: 51-90.
28. Fowler T., Langley K., Rice F., et al. Psychopathy trait scores in adolescents with childhood ADHD: the contribution of genotypes affecting MAOA, 5HTT and COMT activity. Psychiatr Genet. 2009 ; 19: 312-319.
29. Palmason H., Moser D., Sigmund J., et al. Attention-deficit/ hyperactivity disorder phenotype is influenced by a functional catechol-O-methyltransferase variant. J Neural Transm. 2010 ; 117: 259-267.
30. Kopin IJ Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev. 1985 ; 37: 333-364.
31. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006 ; 45: 919-927.